The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 287-292

  Cordoba, I ^a   Gonzalez Porras, J R ^a   Such, E ^b   Nomdedeu, B ^c   Luno E ^d   De Paz, R ^e   Carbonell, F ^f   Vallespi, T ^g   Ardanaz, M ^h   Ramos, F ⁱ   Marco, V ^j   Bonanad, S ^k   Sanchez Barba, M ^l   Costa, D ^c   Bernal, T ^d   Sanz, G F ^b   Canizo M C ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL TXAGORRITXU   (Spain)

ⁱ HOSPITAL DE LEÓN   (Spain)

^j HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^k HOSPITAL DE LA RIBERA   (Spain)

^l CAIBER Investigation Unit   (Spain)

more..

Author keywords

Cytopenia; Myelodysplastic syndrome; Neutropenia; Prognostic; Survival

Indexed keywords

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; NEUTROPENIA; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84855960902     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.10.025     Document Type: Article

References (24)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
3. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
4. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
5. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
6. Kao J.M., McMillan A., Greenberg P.L. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008, 83:765-770.
7. Kantarjian H., Giles F., List A., Lyons R., Sekeres M.A., Pierce S., et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007, 109:1705-1714.
8. Neukirchen J., Blum S., Kuendgen A., Strupp C., Aivado M., Haas R., et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol 2009, 83:477-482.
9. Garcia-Manero G., Shan J., Faderl S., Cortes J., Ravandi F., Borthakur G., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008, 22:538-543.
10. Pomeroy C., Oken M.M., Rydell R.E., Filice G.A. Infection in the myelodysplastic syndromes. Am J Med 1991, 90:338-344.
11. Viscoli C., Varnier O., Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005, 40:S240-S245. (review).
12. Bodey G.P., Buckley M., Sathe Y.S., Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
13. Scott B.L., Park J.Y., Deeg H.J., Marr K.A., Boeckh M., Chauncey T.R., et al. Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant 2008, 14:799-806.
14. Yamaguchi N., Ito Y., Ohyashiki K. Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes. Ann Hematol 2005, 84:383-388.
15. Dayyani F., Conley A.P., Strom S.S., Stevenson W., Cortes J.E., Borthakur G., et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010, 116:2174-2179.
16. Yoshida Y., Hirashima K., Asano S., Takaku F. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991, 78:378-384.
17. Greenberg P., Taylor K., Larson R., et al. Phase II randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood 1993, 82(suppl. 1):196a. [abstract].
18. Negrin R.S., Stein R., Vardiman J., Doherty K., Cornwell J., Krantz S., et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993, 82:737-743.
19. Negrin R.S., Stein R., Doherty K., Cornwell J., Vardiman J., Krantz S., et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996, 87:4076-4081.
20. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M., et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998, 92:68-75.
21. Mantovani L., Lentini G., Hentschel B., Wickramanayake P.D., Loeffler M., Diehl V., et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000, 109:367-375.
22. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarre M.C., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104:321-327.
23. Jadersten M., Montgomery S.M., Dybedal I., Porwit-MacDonald A., Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005, 106:803-811.
24. Greenberg P.L., Sun Z., Miller K.B., Bennett J.M., Tallman M.S., Dewald G., et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009, 114:2393-2400.